Limits...
The role of peptide YY in gastrointestinal diseases and disorders (review).

El-Salhy M, Mazzawi T, Gundersen D, Hatlebakk JG, Hausken T - Int. J. Mol. Med. (2012)

Bottom Line: Abnormalities in PYY seem to contribute to the development of symptoms present in irritable bowel syndrome, inflammatory bowel disease, gastroenteropathy in long-standing diabetes and CST.Similar to other neuroendocrine peptides/amines of the gut, PYY has broad physiological/pharmacological effects: it can bind to and activate several receptors with independent actions.Thus, in order to use PYY as a drug, receptor-specific agonists or antagonists need to be developed.

View Article: PubMed Central - PubMed

Affiliation: Section for Gastroenterology, Department of Medicine, Stord Helse-Fonna Hospital, Stord, Norway. magdy.el-salhy@helse-fonna.no

ABSTRACT
Peptide YY (PYY) is affected in several gastrointestinal diseases and disorders. Changes in PYY appear to be an adaptive response to alterations in pathophysiological conditions caused by the disease. This applies to gastrointestinal diseases/disorders such as irritable bowel syndrome, inflammatory bowel disease, celiac disease, systemic sclerosis, and post-intestinal resection. By contrast, the changes in PYY in chronic idiopathic slow transit constipation (CST) seem to be of a primary nature, and may be one etiological factor of the disease. Abnormalities in PYY seem to contribute to the development of symptoms present in irritable bowel syndrome, inflammatory bowel disease, gastroenteropathy in long-standing diabetes and CST. The changes in PYY could, however, be favorable in some gastrointestinal disorders such as celiac disease, systemic sclerosis and post-intestinal resection state. Investigating changes in PYY in gastrointestinal diseases/disorders could be beneficial in clinical practice, where a receptor agonist or an antagonist can be used as a drug, depending on the condition. Similar to other neuroendocrine peptides/amines of the gut, PYY has broad physiological/pharmacological effects: it can bind to and activate several receptors with independent actions. Thus, in order to use PYY as a drug, receptor-specific agonists or antagonists need to be developed.

Show MeSH

Related in: MedlinePlus

PYY-immunoreactive cells in the colon of (A) a healthy volunteer and (B) a patient withlymphocytic colitis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4042877&req=5

f3-ijmm-31-02-0275: PYY-immunoreactive cells in the colon of (A) a healthy volunteer and (B) a patient withlymphocytic colitis.

Mentions: Colonic PYY cell area was found to be decreased in patients with UC and CD (Fig. 2), whereas those with serotonin andenteroglucagon immunoreactivities were elevated (52). As enteroglucagon and PYY are colocalized in the samecolorectal endocrine cell type (L-cells) (53–55), it appearsthat this cell increased its expression of enteroglucagon, and reduced expression of PYY. Inthe ileal mucosa of patients with CD, PYY cell density was decreased, as was that ofserotonin (56). In one study,serotonin cell density in rectal biopsies from patients with UC was found to be elevated(57), whereas another study showedit to be decreased (28). In rectalbiopsies from patients with UC, mucosal serotonin, tryptophan hydroxylase 1 messenger RNA,serotonin transporter messenger, and serotonin transporter were all reduced (28). It has also been shown that patientswith LC have high densities of colonic PYY and serotonin cells (58) (Fig. 3).


The role of peptide YY in gastrointestinal diseases and disorders (review).

El-Salhy M, Mazzawi T, Gundersen D, Hatlebakk JG, Hausken T - Int. J. Mol. Med. (2012)

PYY-immunoreactive cells in the colon of (A) a healthy volunteer and (B) a patient withlymphocytic colitis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4042877&req=5

f3-ijmm-31-02-0275: PYY-immunoreactive cells in the colon of (A) a healthy volunteer and (B) a patient withlymphocytic colitis.
Mentions: Colonic PYY cell area was found to be decreased in patients with UC and CD (Fig. 2), whereas those with serotonin andenteroglucagon immunoreactivities were elevated (52). As enteroglucagon and PYY are colocalized in the samecolorectal endocrine cell type (L-cells) (53–55), it appearsthat this cell increased its expression of enteroglucagon, and reduced expression of PYY. Inthe ileal mucosa of patients with CD, PYY cell density was decreased, as was that ofserotonin (56). In one study,serotonin cell density in rectal biopsies from patients with UC was found to be elevated(57), whereas another study showedit to be decreased (28). In rectalbiopsies from patients with UC, mucosal serotonin, tryptophan hydroxylase 1 messenger RNA,serotonin transporter messenger, and serotonin transporter were all reduced (28). It has also been shown that patientswith LC have high densities of colonic PYY and serotonin cells (58) (Fig. 3).

Bottom Line: Abnormalities in PYY seem to contribute to the development of symptoms present in irritable bowel syndrome, inflammatory bowel disease, gastroenteropathy in long-standing diabetes and CST.Similar to other neuroendocrine peptides/amines of the gut, PYY has broad physiological/pharmacological effects: it can bind to and activate several receptors with independent actions.Thus, in order to use PYY as a drug, receptor-specific agonists or antagonists need to be developed.

View Article: PubMed Central - PubMed

Affiliation: Section for Gastroenterology, Department of Medicine, Stord Helse-Fonna Hospital, Stord, Norway. magdy.el-salhy@helse-fonna.no

ABSTRACT
Peptide YY (PYY) is affected in several gastrointestinal diseases and disorders. Changes in PYY appear to be an adaptive response to alterations in pathophysiological conditions caused by the disease. This applies to gastrointestinal diseases/disorders such as irritable bowel syndrome, inflammatory bowel disease, celiac disease, systemic sclerosis, and post-intestinal resection. By contrast, the changes in PYY in chronic idiopathic slow transit constipation (CST) seem to be of a primary nature, and may be one etiological factor of the disease. Abnormalities in PYY seem to contribute to the development of symptoms present in irritable bowel syndrome, inflammatory bowel disease, gastroenteropathy in long-standing diabetes and CST. The changes in PYY could, however, be favorable in some gastrointestinal disorders such as celiac disease, systemic sclerosis and post-intestinal resection state. Investigating changes in PYY in gastrointestinal diseases/disorders could be beneficial in clinical practice, where a receptor agonist or an antagonist can be used as a drug, depending on the condition. Similar to other neuroendocrine peptides/amines of the gut, PYY has broad physiological/pharmacological effects: it can bind to and activate several receptors with independent actions. Thus, in order to use PYY as a drug, receptor-specific agonists or antagonists need to be developed.

Show MeSH
Related in: MedlinePlus